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Abstract
Temporal lobe epilepsy (TLE) is associated with some of the same neuropathological features as those reported for
early stages of typical Alzheimer’s disease (AD). The APOE ε4 allele is associated with a gene-dose-dependent
increase in AD risk and in the severity of amyloid-b (Ab) pathology. In a study published in the current BMC
Medicine, Sue Griffin and colleagues studied markers of brain resilience in the amputated temporal lobes of TLE
patients. They discovered compelling evidence that the APOE ε3 isoform in TLE patients is apparently more
neuroprotective from Ab toxicity than is the APOE ε4 isoform, as shown by the reduced levels of neuronal damage,
glial activation, and expression of IL-1a in the APOE ε3/ε3 brains. This result points to a new property of APOE
isoforms: not only are APOE ε4 alleles associated with increased brain amyloid plaque burden, but these alleles are
also apparently inferior to APOE ε3 alleles in conveying resistance to Ab neurotoxicity. This ‘double whammy’ result
opens up a new direction for studies aimed at elucidating the relevant neurobiological activities of APOE isoforms
in the pathogenesis of AD.
Please see related article: http://www.biomedcentral.com/1741-7015/10/35
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Background
Alzheimer’s disease (AD) is a progressive neurological
disease and is the most common form of dementia. The
prevalence of AD is aging-related: 10% of people over
65 years old and 50% of people over 85 years old are
affected. The disease course involves unrelenting decor-
tication, with affected people succumbing in a persistent
vegetative state after an approximate 10-year course of
illness. AD is characterized by the accumulation of
extracellular amyloid plaques and intraneuronal neurofi-
brillary tangles as well as profound neuronal loss. This
neuronal loss correlates better with clinical cognitive
status at the time of death than does the burden of
either pathology; therefore, an understanding of the
molecular mechanisms of neurotoxicity (and ‘neuroresi-
lience’) in AD is of paramount interest.
Apolipoprotein E ε4( APOE ε4, gene; apoE4, protein)
is the major identified genetic risk factor for common
sporadic forms of AD, and understanding the relevant
neurobiological activities of APOE isoforms has pre-
sented a major challenge over the past 20 years. Tem-
poral lobe epilepsy (TLE) is associated with some of the
same neuropathological features as those reported for
early stages of typical AD [1]. The changes in neuro-
pathology reported for TLE include accumulation of
amyloid-b (Ab) as senile plaques and increased micro-
glial activation compared to healthy controls. The APOE
ε4 allele in TLE is associated with a gene-dose-depen-
dent increase in plaque density when compared with
brains of APOE ε3/ε3 genotype [2]. An important dis-
tinction is that the TLE brain is assumed not to be as
generally compromised as is the AD brain. Therefore,
the plaque-loaded TLE brain presents an unusual oppor-
tunity to study focal parenchymal cerebral amyloidosis
situated in what is believed to be an otherwise healthy
brain.
In a research article published in the current issue of
BMC Medicine, Sue Griffin and colleagues have investi-
gated the brains of TLE patients with APOE ε3 and
APOE ε4 alleles. By focusing on TLE, Griffin avoided
the confound of the possible underlying vulnerability to
neurotoxicity that might characterize the AD brain.
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ally studied in typical AD, the researchers also avoided
the possibility of aging-related confounds. This research
uncovered compelling evidence that, after correcting for
the differences in plaque density, the apoE3 isoform in
TLE patients is apparently more neuroprotective from
Ab toxicity than is the apoE4 isoform. This conclusion
is supported by the reduced levels of neuronal damage,
glial activation, and interleukin-1a (IL-1a)i nt h eAPOE
ε3/ε3 brains [3] and is consistent with the predictions of
Miyata and Smith, who provided evidence for the differ-
ential antioxidant activities of apoE3 vs apoE4 proteins
[4]. The differential antioxidant activities of apoE iso-
forms are due to the Cys- and Arg- substitutions at the
polymorphic site [5], which are illustrated in Figure 1.
Tissue levels of IL-1a are dependent on APOE isoform
IL-1a is one of the best characterized inflammatory
cytokines, and, in earlier studies, Griffin and colleagues
have previously established that elevation of brain IL-1a
is an important feature of AD. The elevation of IL-1a in
the TLE cases was apparently related to an increase in
the number of activated microglia. Neurons in the
APOE ε3/ε3 brains had twice as many associated micro-
glia per neuron when compared with the respective data
from APOE ε4/ε4 brains. The increased numbers of
microglia per neuron in APOE ε3/ε3 TLE patients were
associated with an increased level of IL-1a mRNA and
protein. The IL-1a mRNA levels were five-fold higher in
the TLE patients compared to healthy controls, but
those levels were independent of APOE isoform. IL-1a
protein levels were four-fold higher in APOE ε3/ε3
patients than that in APOE ε4/ε4 patients. The elevated
IL-1a protein levels in the TLE patients apparently
resulted in increased amyloid precursor protein (APP)
and apoE protein expression as a function of the APOE
isoform. This supports the idea that microglia activation
a n de l e v a t e dI L - 1 a expression may contribute to the
accumulation of APP and apoE, two key proteins known
to be important for increasing the risk of AD pathology
(see [6], for review), and that this will primarily take
place in the APOE ε4/ε4 brain.
Neuronal damage and size are associated with APOE
isoform
There were no differences in the numbers of neurons in
cortical layers III-VI of three specific areas of the tem-
poral lobe in TLE patients depending on APOE isoform
in the Griffin study. The DNA damage in neurons was
also independent of the APOE genotype. However, the
level of DNA damage per neuron was greater in patients
with APOE ε4/ε4 than in those with the APOE ε3/ε3
genotype. Further, the average size of neurons in
patients with APOE ε4/ε4 genotype was unexpectedly
s m a l l e rt h a ni np a t i e n t sw i t hAPOE ε3/ε3 genotype.
Neurons from TLE patients with the APOE ε3/ε3 geno-
type were larger in terms of the size of both the cyto-
plasm as well as the size of their nuclei, and the APOE
ε3/ε3 neurons appeared to have a more normal mor-
phology than did neurons from TLE patients with the
APOE ε4/ε4 genotype. Due to these findings, Griffin et
al. propose that neurons from individuals with APOE
ε3/ε3 isoform are better protected from the damaging
hyperexcitability associated with epilepsy than were the
neurons from TLE patients with APOE ε4/ε4 isoform.
They also noted that this genetic variation of neuronal
sparing may result from typical acute phase responses of
neurons that result in alternate levels of IL-1a,A P P ,
and apoE expression. These same molecules would be
predicted to protect against DNA fragmentation in TLE
Figure 1 Structure of apoE3 and apoE4. The polymorphism at residue 112 (which can be either arginine in apoE4 or cysteine in apoE3) is
believed to underlie the differential antioxidant activities of apoE3 and apoE4 (adapted from [5], with permission).
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mechanisms linking APOE ε4 with a reduction in var-
ious biomarkers of resilience may, at least in part,
underlie the clinical association of the APOE ε4 allele
with one or more of the negative outcome factors when
human TLE is linked to APOE ε4, such as increased ten-
dency toward earlier age at onset of TLE and/or bilater-
ality of hippocampal damage, although not all of these
negative TLE/APOE ε4 associations have been indepen-
dently confirmed [7-19]. IL-1a is also genetically linked
to the risk for developing TLE in at least two indepen-
dent studies [20].
Density of Ab plaques in TLE patients was associated with
APOE isoform
Senile plaques are reported in about 10% of all TLE
cases and are evident at a younger age than that typi-
cally associated with senile plaques in AD [1]. Griffin et
al. describes the occurrence of Ab/apoE immunoreactive
senile plaques in TLE patients as a function of age, in a
distribution similar to that noted in temporal lobes of
early stages of typical AD patients. Ab/apoE immunor-
eactive senile plaques were even found in a 10-year-old
TLE patient, and senile plaques at such early ages sug-
gests that the neuropathology in TLE patients is not
likely to be attributable to the coincidental presence of
AD. Due to the limited number of patients with the
APOE ε4/ε4 genotype, this study does not reveal
whether a specific APOE genotype is associated with
either a higher probability of having senile plaques in
TLE or with a shift in the age of onset for senile plaque
formation. Gouras et al. [2] have previously written in
this topic, reporting that APOE ε4 alleles were asso-
ciated with onset of plaque pathology below the age of
50 years. The role of amyloid plaques in the clinical
phenomena linked to TLE and APOE ε4 [7-19] have not
been systematically studied, although the recent advent
of amyloid plaque imaging PET scanning now enables
the investigation required to answer this question.
Conclusions
Griffin et al. show for the first time that the APOE ε3/ε3
genotype is apparently more neuroprotective than the
APOE ε4/ε4 genotype, as judged by neuronal damage,
glial activation, and brain IL-1a level in TLE patients.
These findings are consistent with the idea that neurons
in TLE patients carrying the APOE ε4 allele are less
resistant to the damaging hyperexcitability associated
with epilepsy and, therefore, these neurons are more
prone to development of DNA damage. In the setting of
aging and AD, however, the lower neuroprotection
activity of apoE4 may underlie the increased risk for AD
in patients carrying the APOE ε4 allele. This finding
opens up new avenues for research aimed at elucidating
the molecular basis for apoE3-mediated neuroprotec-
tion. ApoE3-mimetic drugs are highly sought as poten-
tial AD therapeutics as an example of personalized
medicine based on individual genetic risk. Recent evi-
dence suggests that bexarotene, a retinoic acid RXR
ligand, may be a breakthrough lead in this quest [21]:
the drug appears to act through apoE to cause rapid (i.e.
within 72 hours) clearance of amyloid plaques in a
mouse model of AD. The perfection of apoE-mimetic
drugs [22-31] for AD may well have a beneficial side
effect of yielding compounds that might be also helpful
for mitigating temporal lobe and hippocampal damage
in patients with TLE.
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